DOJ Probes UnitedHealth's Optum and Insurance Division, Impacting Valuation and Integrated Model

The US Department of Justice (DOJ) has intensified an antitrust investigation into UnitedHealth Group's Optum subsidiary and its insurance division, focusing on their relationship and potential impact on competition in healthcare services and insurance markets. This investigation introduces additional regulatory risk, affecting the stock's valuation and analyst expectations. Investors should watch how the DOJ findings intersect with returns, the company's P/E ratio, and the price target range midpoint.